Importance of medication adherence in cardiovascular disease and the value of once-daily treatment regimens
Abstract
An estimated 71 million individuals in the United States are currently diagnosed with cardiovascular disease (CVD). If untreated, CVD conditions such as systemic hypertension, coronary artery disease, and heart failure will have potentially serious and often fatal outcomes. Numerous clinical trials have established a variety of evidence-based medications that are efficacious in the treatment of CVD. These drugs will be ineffective, however, if patients have trouble adhering to their prescribed regimens. In patients with hypertension or heart failure, or in those who have suffered a myocardial infarction, poor adherence to therapies has been linked to a variety of problems, including poor blood pressure control, rehospitalization, and increased healthcare resource utilization. Both the asymptomatic nature of some forms of CVD and the high pill burden associated with certain therapies have been linked to poor adherence. Reducing pill burden through the use of once-daily formulations has proven valuable in improving adherence to evidence-based therapies. This review will discuss the impact of adherence to prescribed therapies for CVD, outline common barriers to adherence, and demonstrate the value of once-daily dosing regimens for improved patient adherence.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The association between hypertension/elevated lipids and reduced persistence likely reflects the asymptomatic nature of these conditions and the pill burden of managing multiple cardiovascular medications.
“This likely reflects both the asymptomatic nature of these conditions—leading to patient perceptions of wellness without medication—and the pill burden associated with managing multiple cardiovascular medications.129”
From Adherence to PCSK9 Inhibitors in Clinical Practice (2026) · cites this paper as [129]
Cites
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974 · see citing works
Patient Adherence and Medical Treatment Outcomes: A Meta-Analysis
Robin DiMatteo, M., Giordani, P. J., Lepper, H. S., & Croghan, T. W. (2002) · Medical Care · doi:10.1097/00005650-200209000-00009 · Cited by 1,490 · see citing works
Physician communication when prescribing new medications
Tarn, D. M., Heritage, J., Paterniti, D. A., Hays, R. D., Kravitz, R. L., & Wenger, N. S. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.17.1855 · Cited by 400 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Zargar, A., & Ito, M. K. (2011) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2011.0004 · Cited by 39 · see citing works
Adherence to PCSK9 Inhibitors in Clinical Practice
Blais, J. E., Zhong, W., Li, C. Y. V., Kongkaew, C., & Chan, A. H. Y. (2026) · JACC: Advances · doi:10.1016/j.jacadv.2026.102733 · Cited by 7 · see citing works
- Authors
- Frishman, W. H.
- Affiliations
- Westchester Medical Center (US)
- Corresponding author
- Frishman, William H.
- ORCID
- Frishman, William H.
- Venue
- Cardiology in Review
- Published
- 2007-09
- Volume
- 15
- Issue
- 5
- Pages
- 257-263
- ISSN
- 1061-5377 (ISSN-L)
- OpenAlex
- W1983991661
- Cited by
- 101
- References
- 3
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 2 · 2023: 3 · 2022: 5 · 2021: 1 · 2020: 2 · 2019: 5 · 2018: 4 · 2017: 2 · 2016: 3 · 2015: 6 · 2014: 6 · 2013: 16 · 2012: 10
- FWCI
- 0.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cardiology in Review (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- medication adherence, cardiovascular disease, once-daily dosing, medication burden, hypertension, heart failure, coronary artery disease, myocardial infarction, barriers to adherence, blood pressure control, hospital readmission, healthcare resource utilization
- MeSH terms
- Antihypertensive Agents, Cardiovascular Diseases, Chronic Disease, Delayed-Action Preparations, Drug Administration Schedule, Drug Therapy, Combination, Heart Failure, Humans, Hypertension, Myocardial Infarction, Patient Compliance, Patient Readmission, Tablets, Treatment Refusal, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
